Atopic Dermatitis and its Management by the First Contact Doctor

Main Article Content

Martha Estefania Pinedo Hurtado
Esmeralda Hernández Lerma
Mario Eduardo Elias Medina
Miguel A. Ramírez-Madrigal
Patricia Flores Troche
Juan Francisco Medina Ledesma

Abstract

Atopic dermatitis is a chronic inflammatory skin disease that affects a large number of pediatric patients between 2 and 17 years of age. Typical symptoms include intense itching, erythema, and scaling of the skin. Atopic dermatitis has been found to be associated with decreased quality of life for patients and their families. Diagnosis is made by clinical evaluation and differential diagnosis with other dermatologic diseases.


Treatment is based on the severity of the disease and the age of the patient. Topical treatments are the first line of treatment, while systemic treatments are reserved for patients with severe atopic dermatitis who do not respond to topical treatments. In addition, other treatments, such as light therapy, biological therapy and allergen-specific immunotherapy, have been evaluated in patients with atopic dermatitis. A multidisciplinary approach and appropriate patient and family education are critical to the successful management of atopic dermatitis in pediatric patients.

Article Details

How to Cite
Hurtado, M. E. P. ., Lerma, E. H., Medina, M. E. E. ., Ramírez-Madrigal, M. A. ., Troche, P. F. ., & Ledesma, J. F. M. (2023). Atopic Dermatitis and its Management by the First Contact Doctor. International Journal of Medical Science and Clinical Research Studies, 3(4), 604–606. https://doi.org/10.47191/ijmscrs/v3-i4-02
Section
Articles

References

I. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet. 1998;351(9111):1225-1232. DOI: 10.1016/S0140-6736(97)07302-9

II. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64(6):476-483. DOI: 10.1136/thx.2008.106609.

III. Aït-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy. 2009;64(1):123-148. DOI: 10.1111/j.1398-9995.2008.01884.x

IV. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251-1258. DOI: 10.1016/j.jaci.2009.10.009

V. Barraza-Villarreal A, Hernández-Cadena L, Moreno-Macias H, Ramírez-Aguilar M, Romieu I. Trends in the prevalence of asthma and other allergic diseases in school children from Cuernavaca, Mexico. Allergy Asthma Proc. 2007;28(3):368-374.

VI. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107(1):3-8. DOI: 10.1067/mai.2001.112262.

VII. Bedolla-Barajas M, Barrera-Zepeda AT, López-Zaldo JB, Morales-Romero. Asthma in Mexican school-age children is not associated with passive smoking or obesity. Asia Pac Allergy. 2013;3(1):42-49. DOI: 10.5415/apallergy.2013.3.1.42

VIII. Bedolla-Barajas M, Ramírez-Cervantes F, Morales-Romero J, Jesús Pérez-Molina J, Meza-López C, Delgado-Figueroa N, et al. A rural environment does not protect against asthma or other allergic diseases amongst Mexican children. Allergol Immunopathol (Madr). 2018;46(1):31-38. DOI: 10.1016/j.aller.2017.01.010

IX. Mancilla-Hernández E, González-Solórzano EV, Medina-Ávalos MÁ, Barnica-Alvarado RH, et al. Prevalence of asthma and its symptoms in school population of Cuernavaca, Morelos, Mexico. Rev Allerg Mex. 2016;63(4):351-357.

X. Mancilla-Hernández E, Medina-Ávalos MA, Barnica-Alvarado RH, Soto-Candia D, Guerrero-Venegas R, Zecua-Nájera Y. Asthma prevalence and symptom ascertainment as risk indicators. Rev Allerg Mex. 2015;62:271-278.

XI. Bedolla-Barajas M, Cuevas-Rios G, Garcia-Barboza E, Barrera-Zepeda AT, Morales-Romero J. Prevalence and factors associated with allergic rhinitis in schoolchildren in Ciudad Guzman, Mexico. Rev Invest Clin. 2010;62(3):244-251. Available at: http://www.medigraphic.com/pdfs/revinvcli/nn-2010/nn103h.pdf

XII. Mancilla-Hernández E, Medina-Ávalos MA, Barnica-Alvarado RH, et al. Prevalence of allergic rhinitis in populations from several Mexican states. Rev Allerg Mex. 2015;62:196-201.

XIII. Bedolla-Barajas M, Barrera- Zepeda AT, Morales-Romero J. Atopic dermatitis in school children in Ciudad Guzmán, Mexico. Prevalence and associated factors. Rev Allerg Mex. 2010;57(3):71-78.

XIV. Zuk M, Tzintzun-Cervantes G, Rojas-Bracho L. Third almanac of air quality data and trends in nine Mexican cities. Mexico: Instituto Nacional de Ecología/Secretaría de Medio Ambiente y Recursos Naturales; 2007.

XV. Program to improve air quality in Salamanca 2007-2012. Mexico: Gobierno del Estado de Guanajuato/Secretaría del Medio Ambiente y Recursos Naturales/Secretaría de Energía/Instituto de Ecología del Estado de Guanajuato/Presidencia Municipal de Salamanca; 2012.

XVI. Rosales-Castillo JA, Borja-Aburto VH, Olaiz, G, Torres-Meza VM, Olaiz-Fernandez G. Acute effects of air pollution on population health: evidence from epidemiological studies. Salud Publica Mex. 2001;43(6):544-555.